Drug intelligence / Profile preview

KD101

Development stage: Phase 1
Lead developer: Kwang Dong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KD101 is a small molecule drug candidate developed by Kwang Dong Pharmaceutical for the oral treatment of obesity. It is classified as a sesquiterpene and terpene, derived from natural sources. Preclinical studies have shown that KD101 promotes energy metabolism without inhibiting appetite and improves obesity-related biomarkers. The drug has undergone phase 1 clinical trials in South Korea for obesity and overweight, but there are no reports of further development or approval as of the latest updates.

Beyond the preview

Go deeper on KD101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD101.

Explore the full profile